Federal Register / Vol. 89, No. 174 / Monday, September 9, 2024 / Notices 73095 

ACTION: Notice of meeting. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC) announces the 

following meeting for the Clinical 

Laboratory Improvement Advisory 

Committee (CLIAC). This is a virtual 

meeting. It is open to the public, limited 

only by the number of webcast lines 

available. Time will be available for 

public comment, and the public is also 

welcome to submit written comments in 

advance of the meeting (see the public 

participation section below). 

DATES: The meeting will be held on 

November 6, 2024, from 11 a.m. to 5 

p.m., EST, and November 7, 2024, from 

11 a.m. to 5 p.m., EST. 

ADDRESSES: This is a virtual meeting. 

Meeting times are tentative and subject 

to change. The confirmed meeting 

times, agenda items, and meeting 

materials, including instructions for 

accessing the live meeting broadcast, 

will be available on the CLIAC website 

at https://www.cdc.gov/cliac. Check the 

website for the web conference link. 

FOR FURTHER INFORMATION CONTACT: 

Heather Stang, M.S., Senior Advisor for 

Clinical Laboratories, Division of 

Laboratory Systems, Center for 

Laboratory Systems and Response, 

Office of Laboratory Science and Safety, 

Centers for Disease Control and 

Prevention, 1600 Clifton Road NE, 

Mailstop V24–3, Atlanta, Georgia 

30329–4027. Telephone: (404) 498– 

2769; Email: HStang@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The Clinical Laboratory 

Improvement Advisory Committee 

(CLIAC) is charged with providing 

scientific and technical advice and 

guidance to the Secretary, Department 

of Health and Human Services; the 

Assistant Secretary for Health; the 

Director, Centers for Disease Control 

and Prevention (CDC); the 

Commissioner, Food and Drug 

Administration (FDA); and the 

Administrator, Centers for Medicare & 

Medicaid Services (CMS). The advice 

and guidance pertain to general issues 

related to improvement in clinical 

laboratory quality and laboratory 

medicine and specific questions related 

to possible revision of the Clinical 

Laboratory Improvement Amendments 

of 1988 (CLIA) standards. Examples 

include providing guidance on studies 

designed to improve quality, safety, 

effectiveness, efficiency, timeliness, 

equity, and patient-centeredness of 

laboratory services; revisions to the 

standards under which clinical 

laboratories are regulated; the impact of 

proposed revisions to the standards on 

medical and laboratory practice; the 

modification of the standards and 

provision of non-regulatory guidelines 

to accommodate technological 

advances, such as new test methods, 

electronic transmission of laboratory 

information, and mechanisms to 

improve the integration of public health 

and clinical laboratory practices. 

Matters to be Considered: The agenda 

will include CDC, CMS, and FDA 

agency updates. Presentations and 

CLIAC discussions will focus on reports 

from two CLIAC workgroups, the 

Biosafety Workgroup and the Next 

Generation Sequencing Workgroup; 

cybersecurity requirements in the 

clinical laboratory; the determination of 

clinically relevant range of values for 

proficiency testing samples; and the 

utilization of remote technology for 

competency assessments. Agenda items 

are subject to change as priorities 

dictate. 

Public Participation 

It is the policy of CLIAC to accept 

written public comments and provide a 

brief period for oral public comments 

pertinent to agenda items. 

Oral Public Comment: Public 

comment periods for each agenda item 

are scheduled immediately prior to the 

Committee discussion period for that 

item. In general, each individual or 

group requesting to present an oral 

comment will be limited to a total time 

of five minutes (unless otherwise 

indicated). Speakers should email 

CLIAC@cdc.gov or notify the contact 

person above (see FOR FURTHER

INFORMATION CONTACT) at least five 

business days prior to the meeting date. 

Written Public Comment: CLIAC 

accepts written comments until the date 

of the meeting (unless otherwise stated). 

However, it is requested that comments 

be submitted at least five business days 

prior to the meeting date so that the 

comments may be made available to the 

Committee for their consideration and 

public distribution. Written comments 

should be submitted by email to 

CLIAC@cdc.gov or to the contact person 

above. All written comments will be 

included in the meeting minutes posted 

on the CLIAC website. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–20252 Filed 9–6–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Solicitation of Nominations for 

Appointment to the Board of Scientific 

Counselors Infectious Diseases 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), within the 

Department of Health and Human 

Services (HHS), is seeking nominations 

for membership on the Board of 

Scientific Counselors Infectious 

Diseases (BSC ID). The BSC ID consists 

of up to 17 experts from authorities 

knowledgeable in the fields relevant to 

the issues addressed by CDC’s infectious 

disease national centers (e.g., respiratory 

diseases, healthcare-associated 

infections, antimicrobial resistance, 

foodborne diseases, zoonotic and vectorborne diseases, sexually transmitted 

diseases, preparedness) and related 

specialties, including clinical and 

public health practice (including state 

and local health departments), 

laboratory practice, research, 

diagnostics, microbiology, immunology, 

molecular biology, bioinformatics, 

infectious disease modeling and 

outbreak analytics, health policy/ 

communications, and industry. 

DATES: Nominations for membership on 

the BSC ID must be received no later 

than October 9, 2024. Packages received 

after this time will not be considered for 

the current membership cycle. 

ADDRESSES: All nominations should be 

mailed to the Centers for Disease 

Control and Prevention, BSC ID, 1600 

Clifton Road NE, Mailstop H16–5, 

Atlanta, Georgia 30329–4027 or emailed 

to SWiley@cdc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Sarah Wiley, M.P.H., Senior Advisor, 

National Center for Emerging and 

Zoonotic Infectious Diseases, Centers for 

Disease Control and Prevention, 1600 


ddrumheller on DSK120RN23PROD with NOTICES1
73096 Federal Register / Vol. 89, No. 174 / Monday, September 9, 2024 / Notices 

Clifton Road NE, Mailstop H16–5, 

Atlanta, Georgia 30329–4027. 

Telephone: (404) 639–4840; Email: 

SWiley@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Nominations are sought for individuals 

who have the expertise and 

qualifications necessary to contribute to 

the accomplishment of the objectives of 

the Board of Scientific Counselors 

Infectious Diseases (BSC ID). Nominees 

will be selected based on expertise in 

the fields of infectious diseases and 

related specialties, including those 

listed above. Federal employees will not 

be considered for membership. 

Members may be invited to serve for up 

to four-year terms. Selection of members 

is based on candidates’ qualifications to 

contribute to the accomplishment of 

BSC ID objectives (https://www.cdc.gov/ 

bscid/php/about/index.html). 

Department of Health and Human 

Services (HHS) policy stipulates that 

committee membership be balanced in 

terms of points of view represented and 

the committee’s function. Appointments 

shall be made without discrimination 

on the basis of age, race, ethnicity, 

gender, sexual orientation, gender 

identity, HIV status, disability, and 

cultural, religious, or socioeconomic 

status. Nominees must be U.S. citizens 

and cannot be full-time employees of 

the U.S. Government. Current 

participation on Federal workgroups or 

prior experience serving on a Federal 

advisory committee does not disqualify 

a candidate; however, HHS policy is to 

avoid excessive individual service on 

advisory committees and multiple 

committee memberships. Board 

members are Special Government 

Employees, requiring the filing of 

financial disclosure reports at the 

beginning of and annually during their 

terms. The Centers for Disease Control 

and Prevention (CDC) reviews potential 

candidates for BSC ID membership each 

year and provides a slate of nominees 

for consideration to the Secretary of 

HHS for final selection. HHS notifies 

selected candidates of their 

appointment near the start of the term 

in October 2025, or as soon as the HHS 

selection process is completed. Note 

that the need for different expertise 

varies from year to year and a candidate 

who is not selected in one year may be 

reconsidered in a subsequent year. 

Candidates should submit the 

following items: 

• Current curriculum vitae, including 

complete contact information 

(telephone numbers, mailing address, 

email address). 

• At least one letter of 

recommendation from person(s) not 

employed by HHS. Candidates may 

submit letter(s) from current HHS 

employees if they wish, but at least one 

letter must be submitted by a person not 

employed by an HHS agency (e.g., CDC, 

National Institutes of Health, Food and 

Drug Administration). 

Nominations may be submitted by the 

candidate or by the person/organization 

recommending the candidate. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2024–20250 Filed 9–6–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Performance Review Board Members 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC) located 

within the Department of Health and 

Human Services (HHS) is publishing the 

names of the Performance Review Board 

Members who are reviewing 

performance of Senior Executive Service 

(SES) members, Title 42 (T42) 

executives, Senior Level (SL), and ST 

(Scientific Professional) employees for 

fiscal year 2024. 

FOR FURTHER INFORMATION CONTACT: Eva 

Osuchukwu, Team Chief, Executive and 

Scientific Resources Office, Human 

Resources Office, Centers for Disease 

Control and Prevention, 11 Corporate 

Square Blvd., Mailstop US11–2, Atlanta, 

Georgia 30341, Telephone (404)783– 

7410. 

SUPPLEMENTARY INFORMATION: 

The Civil Service Reform Act of 1978 

(Pub. L. 95–454, 5 U.S.C. 4314(c)(4)) 

requires that the appointment of 

Performance Review Board Members be 

published in the Federal Register. The 

following persons will serve on the CDC 

Performance Review Board, which will 

oversee the evaluation of performance 

appraisals of Senior Executive Service 

members for the fiscal year 2024 review 

period: 

Arispe, Irma 

Bonander, Jason 

Dauphin, Leslie 

Dulin, Stephanie 

Durst, Kelley 

Ethier, Kathleen, Co-Chair 

George, Dylan 

Kuhnert, Wendi 

Laserson, Kayla 

Perry, Terrance 

Reh, Christopher 

Taylor, Dia, Co-Chair 

Tomlinson, Hank 

Noah Aleshire, 

Chief Regulatory Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 2024–20226 Filed 9–6–24; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Solicitation of Nominations for 

Appointment to the Board of Scientific 

Counselors, National Center for Health 

Statistics 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: In accordance with the 

Federal Advisory Committee Act, the 

Centers for Disease Control and 

Prevention (CDC), within the 

Department of Health and Human 

Services (HHS), is seeking nominations 

for membership on the Board of 

Scientific Counselors, National Center 

for Health Statistics (BSC, NCHS). The 

BSC, NCHS consists of up to 15 experts 

including the Chair in fields associated 

with the scientific and technical 

program objectives of the Center. 

DATES: Nominations for membership on 

the BSC, NCHS will be accepted on a 

rolling basis. To be considered for the 

upcoming nomination slate, 

submissions should be received no later 

than November 22, 2024. Submissions 

received after this time will not be 

considered for the current membership 

cycle. 

ADDRESSES: All nominations should be 

emailed to NCHS-BSCmail@cdc.gov. 

FOR FURTHER INFORMATION CONTACT: 

Naomi Michaelis, M.P.A., Designated 

Federal Officer, Board of Scientific 


ddrumheller on DSK120RN23PROD with NOTICES1